泰沙基因治疗公司（Taysha Gene Therapies, Inc.，股票代码：TSHA）今日盘中大涨7.25%，引起投资者广泛关注。该公司刚刚公布了截至6月30日的季度财报，虽然每股收益略低于预期，但收入增长强劲，超出市场预期。
根据公司发布的财报，泰沙基因治疗公司第二季度调整后每股亏损9美分，与去年同期持平，略低于分析师平均预期的8美分亏损。然而，公司营收同比大幅增长78.6%，达到199万美元，远超分析师预期的160万美元。这一强劲的收入增长可能是推动股价上涨的主要因素之一。
尽管季度业绩喜忧参半，但华尔街分析师对泰沙基因治疗公司保持乐观态度。目前，分析师对该公司股票的平均评级为"买入"，12个月目标价中位数为8.00美元，较上一交易日收盘价2.76美元高出约65.5%。这种积极的市场sentiment也可能促进了今日的股价上涨。值得注意的是，该公司股价今年以来已上涨59.5%，显示出市场对其长期发展前景的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.